|
1
|
Wu M, Dickinson SI, Wang X and Zhang J:
Expression and function of SIRT6 in muscle invasive urothelial
carcinoma of the bladder. Int J Clin Exp Pathol. 7:6504–6513.
2014.PubMed/NCBI
|
|
2
|
Cornu JN, Neuzillet Y, Hervé JM, Yonneau
L, Botto H and Lebret T: Patterns of local recurrence after radical
cystectomy in a contemporary series of patients with
muscle-invasive bladder cancer. World J Urol. 30:821–826. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choi SY, Ryu JH, Chang IH, Kim TH, Myung
SC, Moon YT, Kim KD and Kim JW: Predicting recurrence and
progression of non-muscle-invasive bladder cancer in Korean
patients: A comparison of the EORTC and CUETO models. Korean J
Urol. 55:643–649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vinall RL, Ripoll AZ, Wang S, Pan CX and
deVere White RW: MiR-34a chemosensitizes bladder cancer cells to
cisplatin treatment regardless of p53-Rb pathway status. Int J
Cancer. 130:2526–2538. 2012. View Article : Google Scholar
|
|
5
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Nohata N, Yamasaki T, Gotanda T,
Tachiwada T, et al: Novel oncogenic function of mesoderm
development candidate 1 and its regulation by MiR-574-3p in bladder
cancer cell lines. Int J Oncol. 40:951–959. 2012.
|
|
6
|
Teply BA and Kim JJ: Systemic therapy for
bladder cancer - a medical oncologist's perspective. J Solid
Tumors. 4:25–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dai X, North BJ and Inuzuka H: Negative
regulation of DAB2IP by Akt and SCFFbw7 pathways. Oncotarget.
5:3307–3315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsai Y-S, Lai C-L, Lai C-H, Chang KH, Wu
K, Tseng SF, Fazli L, Gleave M, Xiao G, Gandee L, et al: The role
of homeostatic regulation between tumor suppressor DAB2IP and
oncogenic Skp2 in prostate cancer growth. Oncotarget. 5:6425–6436.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kong Z, Xie D, Boike T, Raghavan P, Burma
S, Chen DJ, Habib AA, Chakraborty A, Hsieh JT and Saha D:
Downregulation of human DAB2IP gene expression in prostate cancer
cells results in resistance to ionizing radiation. Cancer Res.
70:2829–2839. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dote H, Toyooka S, Tsukuda K, Yano M,
Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, et al:
Aberrant promoter methylation in human DAB2 interactive protein
(hDAB2IP) gene in breast cancer. Clin Cancer Res. 10:2082–2089.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yano M, Toyooka S, Tsukuda K, Dote H,
Ouchida M, Hanabata T, Aoe M, Date H, Gazdar AF and Shimizu N:
Aberrant promoter methylation of human DAB2 interactive protein
(hDAB2IP) gene in lung cancers. Int J Cancer. 113:59–66. 2005.
View Article : Google Scholar
|
|
12
|
Duan YF, Li DF, Liu YH, Mei P, Qin YX, Li
LF, Lin QX and Li ZJ: Decreased expression of DAB2IP in pancreatic
cancer with wild-type KRAS. Hepatobiliary Pancreat Dis Int.
12:204–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie D, Gore C, Liu J, Pong RC, Mason R,
Hao G, Long M, Kabbani W, Yu L, Zhang H, et al: Role of DAB2IP in
modulating epithelial-to-mesenchymal transition and prostate cancer
metastasis. Proc Natl Acad Sci USA. 107:2485–2490. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Min J, Zaslavsky A, Fedele G, McLaughlin
SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE,
Beroukhim R, et al: An oncogene-tumor suppressor cascade drives
metastatic prostate cancer by coordinately activating Ras and
nuclear factor-kappaB. Nat Med. 16:286–294. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang J, Wang B, Hui K, Zeng J, Fan J,
Wang X, Hsieh JT, He D and Wu K: miR-92b targets DAB2IP to promote
EMT in bladder cancer migration and invasion. Oncol Rep.
36:1693–1701. 2016.PubMed/NCBI
|
|
16
|
Kutter C and Svoboda P: miRNA, siRNA,
piRNA: Knowns of the unknown. RNA Biol. 5:181–188. 2008. View Article : Google Scholar
|
|
17
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fendler A, Stephan C, Yousef GM and Jung
K: MicroRNAs as regulators of signal transduction in urological
tumors. Clin Chem. 57:954–968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Døssing KBV, Binderup T, Kaczkowski B,
Jacobsen A, Rossing M, Winther O, Federspiel B, Knigge U, Kjær A
and Friis-Hansen L: Down-regulation of miR-129-5p and the let-7
family in neuroendocrine tumors and metastases leads to
up-regulation of their targets Egr1, G3bp1, Hmga2 and Bach1. Genes
(Basel). 6:1–21. 2014.
|
|
21
|
Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie
H, Zhou L, Wu J and Zheng S: MiR-126-3p suppresses tumor metastasis
and angiogenesis of hepatocellular carcinoma by targeting LRP6 and
PIK3R2. J Transl Med. 12:2592014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ujihira T, Ikeda K, Suzuki T, Yamaga R,
Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, et
al: MicroRNA-574-3p, identified by microRNA library-based
functional screening, modulates tamoxifen response in breast
cancer. Sci Rep. 5:76412015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu J, Cheng Y, Li Y, Jin Z, Pan Y, Liu G,
Fu S, Zhang Y, Feng K and Feng Y: microRNA-128 plays a critical
role in human non-small cell lung cancer tumourigenesis,
angiogenesis and lymphangiogenesis by directly targeting vascular
endothelial growth factor-C. Eur J Cancer. 50:2336–2350. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feng Y, Liu J, Kang Y, He Y, Liang B, Yang
P and Yu Z: miR-19a acts as an oncogenic microRNA and is
up-regulated in bladder cancer. J Exp Clin Cancer Res. 33:672014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiu Y, Liu Z, Xia S, Jin C, Yin H, Zhao W
and Wu Q: MicroRNA-137 upregulation increases bladder cancer cell
proliferation and invasion by targeting PAQR3. PLoS One.
9:e1097342014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin T, Dong W, Huang J, Pan Q, Fan X,
Zhang C and Huang L: MicroRNA-143 as a tumor suppressor for bladder
cancer. J Urol. 181:1372–1380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, Chen
H, Mao Y, Lin Y, Luo J, et al: MicroRNA-490-5p inhibits
proliferation of bladder cancer by targeting c-Fos. Biochem Biophys
Res Commun. 441:976–981. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pignot G, Cizeron-Clairac G, Vacher S,
Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B,
Amsellem-Ouazana D, et al: microRNA expression profile in a large
series of bladder tumors: Identification of a 3-miRNA signature
associated with aggressiveness of muscle-invasive bladder cancer.
Int J Cancer. 132:2479–2491. 2013. View Article : Google Scholar
|
|
30
|
Liang Z, Li S, Xu X, Xu X, Wang X, Wu J,
Zhu Y, Hu Z, Lin Y, Mao Y, et al: MicroRNA-576-3p inhibits
proliferation in bladder cancer cells by targeting cyclin D1. Mol
Cells. 38:130–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ichimi T, Enokida H, Okuno Y, Kunimoto R,
Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama
K, et al: Identification of novel microRNA targets based on
microRNA signatures in bladder cancer. Int J Cancer. 125:345–352.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang
S, Wang W, Zhang J and Zhang Y: RNAi-mediated silencing of VEGF-C
inhibits non-small cell lung cancer progression by simultaneously
down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent
axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer.
47:2353–2363. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ronchetti S, Nocentini G, Giunchi L,
Bartoli A, Moraca R, Riccardi C and Migliorati G: Short-term
dexamethasone treatment modulates the expression of the murine TCR
zeta gene locus. Cell Immunol. 178:124–131. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen YJ, Kong ZL, Wan FN, Wang HK, Bian
XJ, Gan HL, Wang CF and Ye DW: Downregulation of DAB2IP results in
cell proliferation and invasion and contributes to unfavorable
outcomes in bladder cancer. Cancer Sci. 105:704–712. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang R, He X, Liu W, Lu M, Hsieh JT and
Min W: AIP1 mediates TNF-alpha-induced ASK1 activation by
facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin
Invest. 111:1933–1943. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie D, Gore C, Zhou J, Pong RC, Zhang H,
Yu L, Vessella RL, Min W and Hsieh JT: DAB2IP coordinates both
PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc
Natl Acad Sci USA. 106:19878–19883. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chekulaeva M and Filipowicz W: Mechanisms
of miRNA-mediated post-transcriptional regulation in animal cells.
Curr Opin Cell Biol. 21:452–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ratert N, Meyer HA, Jung M, Lioudmer P,
Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert
S, et al: miRNA profiling identifies candidate mirnas for bladder
cancer diagnosis and clinical outcome. J Mol Diagn. 15:695–705.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baffa R, Fassan M, Volinia S, O'Hara B,
Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, et
al: MicroRNA expression profiling of human metastatic cancers
identifies cancer gene targets. J Pathol. 219:214–221. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cho WCS: OncomiRs: The discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Geng Q, Fan T, Zhang B, Wang W, Xu Y and
Hu H: Five microRNAs in plasma as novel biomarkers for screening of
early-stage non-small cell lung cancer. Respir Res. 15:1492014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kosaka N, Iguchi H and Ochiya T:
Circulating microRNA in body fluid: A new potential biomarker for
cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cortez MA, Bueso-Ramos C, Ferdin J,
Lopez-Berestein G, Sood AK and Calin GA: MicroRNAs in body fluids -
the mix of hormones and biomarkers. Nat Rev Clin Oncol. 8:467–477.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Szeto CC: Urine miRNA in nephrotic
syndrome. Clin Chim Acta. 436:308–313. 2014. View Article : Google Scholar : PubMed/NCBI
|
